| LPS/TLR4 signal transduction pathway YC Lu, WC Yeh, PS Ohashi Cytokine 42 (2), 145-151, 2008 | 3683 | 2008 |
| Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer E Tran, S Turcotte, A Gros, PF Robbins, YC Lu, ME Dudley, ... Science 344 (6184), 641-645, 2014 | 2424 | 2014 |
| T-cell transfer therapy targeting mutant KRAS in cancer E Tran, PF Robbins, YC Lu, TD Prickett, JJ Gartner, L Jia, A Pasetto, ... New England Journal of Medicine 375 (23), 2255-2262, 2016 | 1253 | 2016 |
| Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells PF Robbins, YC Lu, M El-Gamil, YF Li, C Gross, J Gartner, JC Lin, JK Teer, ... Nature medicine 19 (6), 747, 2013 | 1184 | 2013 |
| Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer N Zacharakis, H Chinnasamy, M Black, H Xu, YC Lu, Z Zheng, A Pasetto, ... Nature medicine 24 (6), 724-730, 2018 | 777 | 2018 |
| Immunogenicity of somatic mutations in human gastrointestinal cancers E Tran, M Ahmadzadeh, YC Lu, A Gros, S Turcotte, PF Robbins, ... Science 350 (6266), 1387-1390, 2015 | 750 | 2015 |
| Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions YC Lu, X Yao, JS Crystal, YF Li, M El-Gamil, C Gross, L Davis, ME Dudley, ... Clinical Cancer Research 20 (13), 3401-3410, 2014 | 440 | 2014 |
| C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a NJ Chen, C Mirtsos, D Suh, YC Lu, WJ Lin, C McKerlie, T Lee, H Baribault, ... Nature 446 (7132), 203-207, 2007 | 321 | 2007 |
| Pilot trial of adoptive transfer of chimeric antigen receptor–transduced T cells targeting EGFRvIII in patients with glioblastoma SL Goff, RA Morgan, JC Yang, RM Sherry, PF Robbins, NP Restifo, ... Journal of immunotherapy 42 (4), 126-135, 2019 | 280 | 2019 |
| Cancer immunotherapy targeting neoantigens YC Lu, PF Robbins Seminars in immunology 28 (1), 22-27, 2016 | 279 | 2016 |
| Treatment of patients with metastatic cancer using a major histocompatibility complex class II–restricted T-cell receptor targeting the cancer germline antigen MAGE-A3 YC Lu, LL Parker, T Lu, Z Zheng, MA Toomey, DE White, X Yao, YF Li, ... Journal of Clinical Oncology 35 (29), 3322, 2017 | 251 | 2017 |
| Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer X Yao, M Ahmadzadeh, YC Lu, DJ Liewehr, ME Dudley, F Liu, ... Blood, The Journal of the American Society of Hematology 119 (24), 5688-5696, 2012 | 229 | 2012 |
| Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers FJ Lowery, S Krishna, R Yossef, NB Parikh, PD Chatani, N Zacharakis, ... Science 375 (6583), 877-884, 2022 | 201 | 2022 |
| Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression YC Lu, X Yao, YF Li, M El-Gamil, ME Dudley, JC Yang, JR Almeida, ... The Journal of Immunology 190 (12), 6034-6042, 2013 | 168 | 2013 |
| Differential role for c-Rel and C/EBPβ/δ in TLR-mediated induction of proinflammatory cytokines YC Lu, I Kim, E Lye, F Shen, N Suzuki, S Suzuki, S Gerondakis, S Akira, ... The Journal of Immunology 182 (11), 7212-7221, 2009 | 138 | 2009 |
| Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients G Cafri, R Yossef, A Pasetto, DC Deniger, YC Lu, M Parkhurst, JJ Gartner, ... Nature communications 10 (1), 449, 2019 | 134 | 2019 |
| Immunologic recognition of a shared p53 mutated neoantigen in a patient with metastatic colorectal cancer W Lo, M Parkhurst, PF Robbins, E Tran, YC Lu, L Jia, JJ Gartner, ... Cancer immunology research 7 (4), 534-543, 2019 | 126 | 2019 |
| An efficient single-cell RNA-seq approach to identify neoantigen-specific T cell receptors YC Lu, Z Zheng, PF Robbins, E Tran, TD Prickett, JJ Gartner, YF Li, S Ray, ... Molecular Therapy 26 (2), 379-389, 2018 | 97 | 2018 |
| Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor–engineered T cells targeting common p53 neoantigens in human solid tumors SP Kim, NR Vale, N Zacharakis, S Krishna, Z Yu, B Gasmi, JJ Gartner, ... Cancer immunology research 10 (8), 932-946, 2022 | 62 | 2022 |
| Targeting neoantigens for cancer immunotherapy YC Lu, PF Robbins International immunology 28 (7), 365-370, 2016 | 55 | 2016 |
